These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33184850)

  • 21. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing spontaneous adverse drug reaction reporting in public healthcare setting in Namibia.
    Adenuga BA; Kibuule D; Rennie TW
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):247-253. PubMed ID: 31520574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records.
    Liu F; Jagannatha A; Yu H
    Drug Saf; 2019 Jan; 42(1):95-97. PubMed ID: 30649734
    [No Abstract]   [Full Text] [Related]  

  • 25. [Impact of a regional pharmacovigilance network on notification of adverse drug reactions: results at 3 years].
    Picard S; Polard E; Oger E; Bellissant E
    Therapie; 2015; 70(3):293-9. PubMed ID: 25534522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme.
    Carnovale C; Gentili M; Fortino I; Merlino L; Clementi E; Radice S; ViGer Group
    Expert Opin Drug Saf; 2016; 15(2):131-9. PubMed ID: 26882049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacovigilance: Importance, concepts, and processes.
    Kumar A
    Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
    [No Abstract]   [Full Text] [Related]  

  • 29. Case-non-case studies: Principle, methods, bias and interpretation.
    Faillie JL
    Therapie; 2019 Apr; 74(2):225-232. PubMed ID: 30773344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacovigilance in Germany : It is about time].
    Douros A; Schaefer C; Kreutz R; Garbe E
    Internist (Berl); 2016 Jun; 57(6):616-23. PubMed ID: 27224991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.
    Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A
    Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [From pharmacovigilance to pharmacoepidemiology and risk coordination].
    Montastruc JL
    Rev Med Interne; 2009 Dec; 30 Suppl 4():S281-90. PubMed ID: 19892443
    [No Abstract]   [Full Text] [Related]  

  • 33. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study.
    Schutte T; Tichelaar J; Reumerman MO; van Eekeren R; Rolfes L; van Puijenbroek EP; Richir MC; van Agtmael MA
    Drug Saf; 2017 May; 40(5):409-418. PubMed ID: 28120270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse drug reactions in elderly: a five-year review of spontaneous reports to the Portuguese pharmacovigilance system.
    Monteiro C; Duarte AP; Alves G
    Expert Opin Drug Saf; 2021 Jan; 20(1):109-118. PubMed ID: 33170742
    [No Abstract]   [Full Text] [Related]  

  • 36. Diverging approaches of pharmacovigilance and pharmacoepidemiology to assessing drug safety: epistemological and ethical implications.
    Coste J
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):600-602. PubMed ID: 28239922
    [No Abstract]   [Full Text] [Related]  

  • 37. Report of Adverse Events in Colombia: A Successful Case.
    Moreno-Mattar O; Ramírez R; Alvarado A; Sierra F; Guzmán J
    Curr Drug Saf; 2019; 14(1):53-56. PubMed ID: 30411692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Encouraging spontaneous reporting of adverse effects.
    Prescrire Int; 2015 Feb; 24(157):53. PubMed ID: 25802925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of Augmented Intelligence for Pharmacovigilance Case Seriousness Determination.
    Routray R; Tetarenko N; Abu-Assal C; Mockute R; Assuncao B; Chen H; Bao S; Danysz K; Desai S; Cicirello S; Willis V; Alford SH; Krishnamurthy V; Mingle E
    Drug Saf; 2020 Jan; 43(1):57-66. PubMed ID: 31605285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The value of case reports in pharmacovigilance.
    Garcia-Doval I; Segovia E; Hunter H; Frew J; Naldi L
    Br J Dermatol; 2020 Nov; 183(5):795-796. PubMed ID: 33135791
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.